Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference

Wednesday, November 5, 2008 General News
Email Print This Page Comment
Font : A-A+

LA JOLLA, Calif., Nov. 4 Dr. Juliet Singh,President and Chief Executive Officer of Transdel Pharmaceuticals, Inc.(OTC Bulletin Board: TDLP, http://www.transdelpharma.com), will present at theRodman & Renshaw Annual Global Healthcare Conference at the Palace Hotel inNew York City. The Transdel presentation will be given in the Kennedy II roomon the fourth floor of the hotel on Tuesday, November 11th at 2:25PM EST.

To listen to the audio web cast of the presentation, please visit theInvestor Relations section of the Company's website athttp://www.transdelpharma.com. An archive of the presentation will beavailable for replay for thirty days.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceuticalcompany developing non-invasive, topically delivered medications. TheCompany's innovative-patented proprietary Transdel(TM) cream formulationtechnology is designed to facilitate the effective penetration of drugsthrough the tough skin barrier to reach the target underlying tissues. In thecase of Ketotransdel(TM), the Transdel(TM) cream allows the active ingredientketoprofen to reach the target soft tissue and exert its well-knownanti-inflammatory and analgesic effects. The Company is also investigatingother drug candidates and treatments for transdermal delivery using thepatented Transdel(TM) platform technology for products in pain management andother therapeutic areas. For more information, please visithttp://www.transdelpharma.com.

Safe Harbor Statement

The statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.

SOURCE Transdel Pharmaceuticals, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook